Project Grant HT94252510128
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$889K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This federal Project Grant award of $901,954 from the Defense Health Agency supports research led by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to assess the molecular basis of microbiome-gut-brain signaling in autism spectrum disorder. The research will utilize a humanized zonulin transgenic mouse model and human intestinal organoids. This work is funded under the Military Medical Research and Development program (CFDA 12.420), which provides...
This $1,234,505 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), in conducting research to revolutionize antibody-drug conjugate therapy for refractory breast cancers. The project aims to cotarget the tumor microenvironment to improve the efficacy of antibody-drug conjugate therapies for challenging breast cancer cases....
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $577,094 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "Redirecting Viral Immunity to Eradicate Low Tumor Mutation Burden Lung Cancers." The award period runs from Aug 31, 2023 to Aug 29, 2025. As a leading academic medical center and research institution, MGH utilizes its...
The federal Project Grant award of $1,618,114 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to define the role of anti-nephrin antibodies in the recurrence of focal segmental glomerulosclerosis post-transplantation. This foundational biomedical research project, which began on April 1, 2025 and is scheduled for completion by...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $730,033 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for research to develop therapies targeting AMH signaling within the ovarian cancer tumor microenvironment. The award has a performance period from April 15, 2024 to April 14, 2027. As part of its extensive biomedical research portfolio,...
The U.S. Defense Health Agency awarded a $1,644,309 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The General Hospital Corporation's Research Management Division, doing business as Massachusetts General Hospital (MGH), with a performance period from February 1, 2025 to January 31, 2028. The grant supports research to study "Functional Molecular Networks Modifying HIF2A Activity in VHL Tumors". Through this award, MGH will conduct...
The Defense Health Agency awarded Massachusetts General Hospital a $368,238 project grant under the Military Medical Research and Development program (CFDA 12.420) from September 1, 2023 through August 31, 2026. The grant will fund research to determine if microbiome-derived cell fragments in the brain accelerate transition from traumatic brain injury to Alzheimer's disease or related dementias. As a leading academic medical center, Massachusetts General Hospital will leverage its expertise...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), received a $1,865,846 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on July 1, 2024. The funding will support the project "TARGETING NEUROIMMUNE AND EPITHELIAL SIGNALING FOR ECZEMA TREATMENT" through June 30, 2028. MGH, a leading academic medical center and research institution, will conduct biomedical research,...
The Project Grant award of $320,000 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The General Hospital Corporation (Massachusetts General Hospital) for the research project "GAMMA DELTA T CELL LIGANDS IN MS". The award runs from November 1, 2024 to October 31, 2026 and will fund research to investigate the role of gamma delta T cell ligands in multiple sclerosis. The General Hospital Corporation, a non-profit...
The General Hospital Corporation, doing business as Massachusetts General Hospital, received a $587,117 project grant from the Defense Health Agency's Military Medical Research and Development program to develop an online platform promoting evidence-based care for patients with neurofibromatosis 1. The three-year grant, awarded June 1, 2023 and set to be completed by May 31, 2026, aims to address medical and social barriers to care through tailoring an online resource to provide specialized...